Short answer
SELLAS Life Sciences Group, Inc. (SLS) filed an 8-K current report with the SEC on July 27, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events). Preliminary unaudited cash and cash equivalents of $138.3 million as of June 30, 2026.
SELLAS Life Sciences Group, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Preliminary unaudited cash and cash equivalents of $138.3 million as of June 30, 2026
- Six-month financial closing procedures remain incomplete, creating potential for material adjustment
- Cash position provides an early liquidity indicator ahead of finalized financial statements
Item 8.01 · Other Events
- Arbitration claims against 3D Medicines dismissed on July 24, 2026
- SLS responsible for approximately $1.0 million of 3D Medicines’ legal fees and costs
- 3D Medicines continuing GPS development and commercialization in Greater China
- $191.5 million in potential future milestones remain, including disputed $13.0 million payments
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other SELLAS Life Sciences Group, Inc. 8-K filings
Get the next SLS 8-K as it lands
Follow SLS for push alerts, or ask the research agent what this filing means.